- Trials with a EudraCT protocol (71)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
71 result(s) found for: Business case.
Displaying page 1 of 4.
EudraCT Number: 2015-002644-14 | Sponsor Protocol Number: | Start Date*: 2015-09-15 | |||||||||||
Sponsor Name:Alder Hey Children's NHS Foundation Trust | |||||||||||||
Full Title: POPPET Study - Pharmacokinetics of continuous administration of Piperacillin/Tazobactam to children using an elastomeric pump | |||||||||||||
Medical condition: Febrile Neutropenia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000819-25 | Sponsor Protocol Number: DS102A-05-AH1 | Start Date*: 2019-01-31 | |||||||||||
Sponsor Name:Afimmune | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients with Severe Acute Decompensated Alcoholic Hepatitis. | |||||||||||||
Medical condition: Severe Acute Decompensated Alcoholic Hepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) LV (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000365-12 | Sponsor Protocol Number: CAFQ056A2166 | Start Date*: 2011-04-21 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, open-label, five period, crossover study to evaluate the single dose pharmacokinetics and food effect of two pediatric AFQ056 formulations in healthy adults | ||
Medical condition: Not Applicable. This is a PK study (including evaluation of food effect). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017525-19 | Sponsor Protocol Number: 77777 | Start Date*: 2010-03-12 |
Sponsor Name:St. Vincents University Hospital, Department of Rheumatology. | ||
Full Title: Abatacept in Psoriasis and Psoriatic Arthritis: a single centre, placebo-controlled, crossover study in 15 patients. | ||
Medical condition: Psoriatic Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000661-19 | Sponsor Protocol Number: CFEM345EGB07 | Start Date*: 2005-11-04 |
Sponsor Name:Novartis Pharmaceuticals UK Ltd | ||
Full Title: Neoadjuvant hormone therapy for postmenopausal women with ER and/or PgR positive primary breast cancer: A multi-center study to determine the optimum length of treatment with Femara (letrozole 2.5m... | ||
Medical condition: Postmenopausal women with ER and/or PgR positive primary breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-004064-35 | Sponsor Protocol Number: | Start Date*: 2018-04-17 |
Sponsor Name:Southern Health NHS Foundation Trust | ||
Full Title: Liraglutide and the management of overweight and obesity in people with schizophrenia: a pilot study | ||
Medical condition: Schizophrenia, schizoaffective disorder or first episode psychosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005626-19 | Sponsor Protocol Number: CVT-301-004E | Start Date*: 2016-06-23 | |||||||||||
Sponsor Name:Civitas Therapeutics, Inc. | |||||||||||||
Full Title: A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) | |||||||||||||
Medical condition: Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002482-15 | Sponsor Protocol Number: M23-696 | Start Date*: 2022-12-27 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG (AbbVie) | |||||||||||||
Full Title: A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to Severe Atopic Derm... | |||||||||||||
Medical condition: Moderate to Severe Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) HU (Completed) SK (Completed) SE (Completed) FR (Completed) PL (Completed) IT (Completed) PT (Completed) DK (Completed) NL (Completed) GR (Completed) BE (Completed) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004438-24 | Sponsor Protocol Number: M14-483 | Start Date*: 2015-06-23 | ||||||||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||||||||||||||||||
Full Title: INTELLANCE 2: ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group. | ||||||||||||||||||
Medical condition: Glioblastoma Multiforme For Pediatric - High Grade Glioma and DIPG | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) DE (Completed) HU (Completed) AT (Completed) FI (Completed) GB (Completed) IE (Completed) ES (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005067-17 | Sponsor Protocol Number: CVT-301-004 | Start Date*: 2016-04-01 | |||||||||||
Sponsor Name:Civitas Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluct... | |||||||||||||
Medical condition: Parkinson's Disease With Motor Response Fluctuations (OFF Phenomena) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000171-17 | Sponsor Protocol Number: SPD405-207 | Start Date*: 2012-10-02 | |||||||||||
Sponsor Name:Shire Pharmaceutical Development Ltd. | |||||||||||||
Full Title: A Three Part Open-Label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, compare the Efficacy, Safety and Tolerability of 8 weeks treatment with Lanthanum Carbonate and Calcium Carbonat... | |||||||||||||
Medical condition: Treatment of Hyperphosphataemia. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) PL (Completed) Outside EU/EEA CZ (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005924-16 | Sponsor Protocol Number: M13-377 | Start Date*: 2012-06-13 | |||||||||||
Sponsor Name:Abbott Laboratories Ireland Limited | |||||||||||||
Full Title: A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate /Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching M... | |||||||||||||
Medical condition: Dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019872-65 | Sponsor Protocol Number: MK-0663-108 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patie... | |||||||||||||
Medical condition: Ankylosing Spondylitis (AS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) FI (Completed) BE (Completed) AT (Completed) GB (Completed) EE (Completed) SK (Completed) CZ (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020688-18 | Sponsor Protocol Number: CQAX576A2203 | Start Date*: 2011-06-29 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multipledose, exploratory proof of concept study to assess the safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of QAX576 in pa... | |||||||||||||
Medical condition: Patients with rapidly progressive idiopathic pulmonary fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004121-13 | Sponsor Protocol Number: M13-687 | Start Date*: 2015-11-17 | |||||||||||
Sponsor Name:AbbVie GK | |||||||||||||
Full Title: A Multicenter Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Investigate Efficacy, Safety and Pharmacokinetics after Dose Escalation in Japanese Subjects with Crohn's Disease | |||||||||||||
Medical condition: Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003228-19 | Sponsor Protocol Number: EVP-6124-017 | Start Date*: 2014-02-26 | ||||||||||||||||
Sponsor Name:EnVivo Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist, as an ... | ||||||||||||||||||
Medical condition: Cognitive impairment associated with schizophrenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IT (Completed) GB (Completed) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-002554-23 | Sponsor Protocol Number: GENA-05 | Start Date*: 2013-02-19 | |||||||||||
Sponsor Name:OCTAPHARMA AG | |||||||||||||
Full Title: Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII in Previously Untreated Patients with Severe Haemophilia A | |||||||||||||
Medical condition: Severe Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) PL (Completed) DE (Completed) ES (Completed) FR (Completed) PT (Completed) SI (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019871-31 | Sponsor Protocol Number: MK-0663-107 | Start Date*: 2010-10-18 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK- 0663/Etoricoxib in Patients wit... | |||||||||||||
Medical condition: Rheumatoid Arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) BE (Completed) AT (Completed) LT (Completed) GB (Completed) DE (Completed) SK (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000078-31 | Sponsor Protocol Number: ST10-01-305 | Start Date*: 2025-04-09 | |||||||||||
Sponsor Name:Shield TX (UK) Ltd. | |||||||||||||
Full Title: Randomised, open-label, active-controlled, multicentre, comparative study to evaluate the safety and efficacy of ferric maltol (iron(III)-maltol complex) (ST10) oral suspension compared to ferrous ... | |||||||||||||
Medical condition: Iron deficiency anaemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000362-38 | Sponsor Protocol Number: BBW-11 | Start Date*: 2012-06-18 | |||||||||||
Sponsor Name:Birken AG | |||||||||||||
Full Title: Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in... | |||||||||||||
Medical condition: Superficial partial-thickness (grade 2a) burn wounds | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
